Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.79 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.61 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.61 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.61 |
| ▸ | LDHA | P00338 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | FBP1 | P09467 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.61 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.61 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.61 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888085 | 1.00 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL29384615 | 1.00 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL17438017 | 0.96 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL8325770 | 0.94 | ADORA1 (0.85) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL30670292 | 0.92 | ADORA1 (0.76) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL4296364 | 0.92 | ADORA1 (0.69) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL15329077 | 0.92 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL30582997 | 0.92 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL21314872 | 0.90 | ADORA1 (0.64) | ADORA1SMN1; SMN2 | |
| SCHEMBL29384896 | 0.90 | ADORA1 (0.64) | ADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3434773-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-10144928-B2 | Double stranded oligonucleotide compounds comprising positional modifications | QUARK PHARMACEUTICALS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-10093923-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2018-10-09 | — | — | US | disclosed |
| US-10059942-B2 | Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues | BIO-LAB LTD. (IL) | 2018-08-28 | — | — | US | disclosed |
| EP-2855679-B1 | THERAPEUTIC OLIGONUCLEOTIDES COMPRISING PYRAZOLOTRIAZINE NUCLEOTIDE ANALOGUES | QBI ENTPR LTD (IL) | 2018-07-18 | — | — | EP | disclosed |
| EP-2521783-B1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS INC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2585594-B1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160355805-A1 | Double Stranded Oligonucleotide Compounds Comprising Positional Modifications | QUARK PHARMACEUTICALS, INC. | 2016-12-08 | — | — | US | disclosed |
| EP-2649181-B1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS INC (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-3012324-A2 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Corporation (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-20150166990-A1 | THERAPEUTIC OLIGONUCLEOTIDES COMPRISING PYRAZOLOTRIAZINE NUCLEOTIDE ANALOGUES | BIO-LAB LTD. (IL) | 2015-06-18 | — | — | US | disclosed |
| US-20150159154-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-9045755-B2 | Double stranded RNA compounds to RhoA and use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8859751-B2 | Oligonucleotide compounds comprising non-nucleotide overhangs | QUARK PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140235695-A1 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION | 2014-08-21 | — | — | US | disclosed |
| US-8710209-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2014-04-29 | — | — | US | disclosed |
| US-20130324591-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130137750-A1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130035368-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Technical Corporation | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | HSPA1A, HSPH1, HSPA8 | ADORA1 4226/4885DNPH1 2839/4885PRKAB2 2167/4885 |
| US-20130035368-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | DCLRE1B, SNRPE, UPF1 | ADORA1 1401/4885DNPH1 4620/4885PRKAB2 1294/4885 |
| US-10093923-B2 | Modulation of HSP47 expression | HSPA1A, HSPH1, HSPA8 | ADORA1 4226/4885DNPH1 2839/4885PRKAB2 2167/4885 |
| US-10059942-B2 | Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues | RNASEH1, RNGTT, EIF2AK2 | ADORA1 1019/4885DNPH1 2139/4885PRKAB2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.